Information de reference pour ce titreAccession Number: | 00000889-201203000-00035.
|
Author: | Bulua, Ariel C. 1; Mogul, Douglas B. 1,+; Aksentijevich, Ivona 1,++; Singh, Harjot 1; He, David Y. 2; Muenz, Larry R. 2; Ward, Michael M. 1; Yarboro, Cheryl H. 1; Kastner, Daniel L. 1,+; Siegel, Richard M. 1,*; Hull, Keith M. 1
|
Institution: | (1) National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland (2) Larry R. Muenz and Associates, Gaithersburg, Maryland (+) Johns Hopkins Children's Center, Baltimore, Maryland (++) National Human Genome Research Institute, NIH, Bethesda, Maryland (*) National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Building 10, Room 13C103, Bethesda, MD 20892
|
Title: | |
Source: | Arthritis & Rheumatism. 64(3):908-913, March 2012.
|
Abstract: | Objective. To investigate the efficacy of etanercept in improving the symptoms and underlying inflammation in patients with tumor necrosis factor receptor-associated periodic syndrome (TRAPS).
Methods. Fifteen patients with TRAPS were enrolled in a prospective, open-label, dose-escalation study. Patients recorded attacks, symptom severity, and use of ancillary medications in a daily diary. Blood samples were collected during each period and measured for levels of acute-phase reactants. Between 7 years and 9 years after the conclusion of the initial study, patients completed a followup survey and were evaluated to determine the long-term outcome of etanercept treatment.
Results. Etanercept treatment significantly attenuated the total symptom score and reduced the frequency of symptoms. Etanercept also reduced levels of acute-phase reactants, particularly during asymptomatic periods. During a 10-year followup period, patients continued to receive etanercept for a median of 3.3 years, with a number of patients switching to anti-interleukin-1[beta] receptor therapy or not receiving biologic agents, most frequently citing injection site reactions and lack of efficacy as reasons for discontinuation. However, patients continuing to receive etanercept had reduced symptoms at followup.
Conclusion. Etanercept reduces symptoms and serum levels of inflammatory markers of TRAPS in a dose-dependent manner, but does not completely normalize symptoms or acute-phase reactant levels. Although long-term adherence to etanercept is poor, continuing to receive etanercept may provide continued symptomatic benefit.
(C) 2012, American College of Rheumatology
|
References: | 1. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med, 1999; 340: 253-9.
2. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell, 1999; 97: 133-44.
3. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol, 2009; 27: 621-68.
4. Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore), 2002; 81: 349-68.
5. Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, Hull KM, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood, 2006; 108: 1320-7.
6. Pelagatti MA, Meini A, Caorsi R, Cattalini M, Federici S, Zulian F, et al. Long-term clinical profile of children with the low penetrance R92Q mutation of the TNFRSF1A gene. Arthritis Rheum, 2011; 63: 1141-50.
7. Simon A, Bodar EJ, van der Hilst JC, van der Meer JW, Fiselier TJ, Cuppen MP, et al. Beneficial response to interleukin 1 receptor antagonist in TRAPS. Am J Med, 2004; 117: 208-10.
8. Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med, 2011; 208: 519-33.
9. Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. [published erratum appears in Rheumatology (Oxford) 2003;42:711]. Rheumatology (Oxford), 2003; 42: 235-9.
10. Quillinan N, Mannion G, Mohammad A, Coughlan R, Dickie LJ, McDermott MF, et al. Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Ann Rheum Dis, 2011; 70: 1692-3.
11. Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum, 2008; 58: 1516-20.
12. Vaitla PM, Radford PM, Tighe PJ, Powell RJ, McDermott EM, Todd I, et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum, 2011; 63: 1151-5.
13. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet, 2001; 358: 24-9.
14. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis, 2010; 69: 2002-8.
15. Weinblatt ME, Bathon JM, Kremer JM, Fleischmann RM, Schiff MH, Martin RW, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken), 2011; 63: 373-82.
|
Language: | English.
|
Document Type: | Autoinflammatory Disease.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0004-3591
|
NLM Journal Code: | 0370605, 90m
|
DOI Number: | https://dx.doi.org/10.1002/art.3...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|